Ignite Creation Date:
2025-12-24 @ 3:06 PM
Ignite Modification Date:
2025-12-27 @ 9:12 PM
Study NCT ID:
NCT05248659
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-12-09
First Post:
2022-02-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-04-05
Start Date Type:
ACTUAL
Primary Completion Date:
2028-12-28
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-12-28
Completion Date Type:
ESTIMATED
First Submit Date:
2022-02-18
First Submit QC Date:
None
Study First Post Date:
2022-02-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-04
Last Update Post Date:
2024-12-09
Last Update Post Date Type:
ACTUAL